Chemours - CC Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CC, but not buy additional shares or sell existing shares.
View CC analyst ratings or view top-rated stocks.

11 brokers have issued 12 month price targets for Chemours' shares. Their CC share price forecasts range from $24.00 to $43.00. On average, they predict the company's stock price to reach $34.10 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts price targets for CC or view top-rated stocks among Wall Street analysts.

Chemours' stock was trading at $30.62 at the start of the year. Since then, CC stock has increased by 17.2% and is now trading at $35.89.
View the best growth stocks for 2023 here.

Chemours saw a decline in short interest in January. As of January 15th, there was short interest totaling 3,860,000 shares, a decline of 7.0% from the December 31st total of 4,150,000 shares. Based on an average daily trading volume, of 1,190,000 shares, the short-interest ratio is currently 3.2 days. Currently, 2.6% of the shares of the company are sold short.
View Chemours' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our CC earnings forecast.

Chemours will be holding an earnings conference call on Friday, February 10th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

The Chemours Company (NYSE:CC) issued its quarterly earnings results on Thursday, November, 4th. The specialty chemicals company reported $1.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.28. The specialty chemicals company earned $1.68 billion during the quarter, compared to analyst estimates of $1.58 billion. Chemours had a net margin of 12.91% and a trailing twelve-month return on equity of 73.45%. Chemours's quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.47 EPS.

Chemours declared a quarterly dividend on Tuesday, October 25th. Stockholders of record on Tuesday, November 15th will be paid a dividend of $0.25 per share on Thursday, December 15th. This represents a $1.00 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Monday, November 14th.
Read our dividend analysis for CC.

Chemours (NYSE:CC) pays an annual dividend of $1.00 per share and currently has a dividend yield of 2.75%. The dividend payout ratio is 17.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CC will have a dividend payout ratio of 23.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CC.

106 employees have rated Chemours Chief Executive Officer Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.85%), Folger Nolan Fleming Douglas Capital Management Inc. (0.48%), Private Management Group Inc. (0.34%), Hancock Whitney Corp (0.19%), New York State Teachers Retirement System (0.15%) and Wedge Capital Management L L P NC (0.14%). Insiders that own company stock include Alisha Bellezza, Alvenia Scarborough, David C Shelton, Denise Dignam, E Bryan Snell, Edwin C Sparks, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mark P Vergnano, Matthew S Abbott, Richard H Brown and Sameer Ralhan.
View institutional ownership trends.

Shares of CC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $35.89.

Chemours (NYSE:CC) has a market capitalization of $5.42 billion and generates $6.35 billion in revenue each year. The specialty chemicals company earns $608 million in net income (profit) each year or $5.61 on an earnings per share basis.

The company employs 6,400 workers across the globe.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The official website for the company is www.chemours.com. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at investor@chemours.com.